API

Golimumab

Drug classification

Immunosuppressant (tumor necrosis factor (TNF) alpha inhibitor)

Dosage form

Solution For Injection

API strength per dosage

50 mg/0.5 m

Dose

For adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, administer Golimumab 50 mg subcutaneously once a month. For pediatric ulcerative colitis (ages 2-17), dosing is weight-based: 80 mg if ≥40 kg; 40 mg if <40 kg. Adjustments may be needed for renal or hepatic impairment.

Mechanism of action

Golimumab is a human monoclonal antibody that binds to tumor necrosis factor alpha (TNFα), inhibiting its interaction with TNF receptors, thereby reducing inflammation and modulating immune responses.

Indications

Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis.

Side effects

Pregnancy category

Precautions

Contraindications